Drawing for Serial No. 79070127

USPTO serial 79070127

Serial No. 79070127

Reviewed by CopyMark Law Group

Status 404
Filing date
Status date
Registration date
—
Examiner
LOTT, MAUREEN DALL
Law office
LAW OFFICE 117 - EXAMINING ATTORNEY ASSIGNED

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with Serial No. 79070127?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
003Essential oils for use in the manufacture of cosmetics, hair lotions and perfumery; hair lotions; dentifricesACTIVE—
005Pharmaceutical preparations for use in the treatment, cure, mitigation or prevention of gingivitis, halitosis, stomatitis, periodontitis, inflammation of the oral cavity and pharyngeal cavity, hypersensitivity of teeth, angina, atherosclerosis, bronchial asthma, circulatory disorders, constipation, diarrhoea, heart failure, heart rhythm disorders, high blood pressure, indigestion, insomnia, migraine, motion sickness, nausea, peptic ulcers, vomiting, allergy, gynaecological disorders affecting menstruation, sterility, menstrual syndromes, dysmenorrhoea, infertility, genital tract infections, pelvic inflammatory diseases, vaginal discomfort due to menopausal atrophic changes, anatomical abnormalities, neoplasia, breast neoplasm, breast cancer, mamma, mastopathy, mastodynia, premenstrual syndrome, climateric complaints, breast pain, blood conditions and disorders, blood circulation disorders, high blood pressure, hypertension, pulmonary diseases, heart rhythm disorders, heart failure, urological diseases, sexually transmitted diseases and inflammatory pelvic diseases, menopausal complaints due to therapeutically induced menopause, tamoxifen induced hot flushes of breast cancer survivors, vaginal discomfort due to menopausal atrophic changes, climactic sleep disturbances, depressive moods, osteoprotectio, osteoporosis, central nervous system infections, brain diseases, central nervous system movement disorders, ocular motility disorders, spinal cord diseases, psycho vegetative disorders, depressive syndrome, anxiety, nervous unrest, peripheral nervous system infections, peripheral nervous system movement disorders, nerve compression syndromes, neuritis, neuralgia and regional pain syndromes, diseases and disorders of the kidney, urological disorders, chronic infections of the bladder, cystitis, pyelonephritis, glomerulonephritis, interstitial nephritis, neprholithiasis, cancer, urolith prophylaxis, dizziness, migraine, depression, inflammations of the upper and lower respiratory organs, sinuses, bronchitis, tonsillitis, arthritis, osteoarthritis, fever, cough, cold, Alzheimer's disease, infection of respiratory tract, infection of urinary tract, urinary obstruction, chronic venous insufficiency, prostate hyperplasia, muscle pains, soft tissue rheumatism, musculoskeletal disease, liver disease, hepatitis, cirrhosis of liver, periodontal diseases and dental caries; pharmaceutical preparations for use as an antidepressant, diuretic, hypnotic, sedative, stimulant and tranquilizer; haemorrhoidal ointment, laxative, nasal decongestant capsules, nasal spray preparations, non-narcotic analgesics, throat lozenges; medicinal preparations in tablet form, namely menstruation circulation regulating tablets; pharmaceutical preparations, namely for hormone regulation and hormone replacement; pharmaceutical preparations for sensory organs, namely for use in ophthalmology, otolaryngology and dermatology; pharmaceutical preparations for regulation and strengthening of the immune system; pharmaceutical preparations for treating temporary relief of occasional minor irritation, pain, sore mouth, sore gums, sore throat, pain associated with canker sores, pain due to minor irritation or injury of the mouth and gums, pain due to minor dental procedures, pain due to minor irritations caused by dentures or orthodontic appliances, sore gums due to teething in infants and children four months of age and older; pharmaceutical products, namely medicated dental, gum and mouth washes, medicated dental, gum and mouth rinse, medicated toothpastes, medicated oral care gels, medicated dental gels, medicated lozenges, cough lozenges, medicated chewing gum, medicated gels and fluids in the nature of medicated balms, medicated dental tapes, medicated dental ribbons, medicated dental polish; pharmaceutical preparations for dental purposes, namely plaque disclosing reagents, periodontal diagnostic reagents for medical purposes for detecting derivatives from periodontal bacteria and caries, diagnostic reagents for detecting derivatives from caries-causal bacteria and medicines for the prevention and treatment of periodontal diseases, dental caries, canker sores, cold sores, mucositis and oral and tongue cancers; medicated mouth sprays; plant extracts for veterinary and pharmaceutical purposes; sanitary preparations for medical use; sanitary preparations for hygiene, namely antiseptics, oral antiseptics, disinfectants for health purposes; sanitary preparations for the treatment, cleaning and protection of the skin; dietary supplements in the form of tablets, drops, capsules, extract preparations, balms or in liquid form, containing plant extracts; dietetic foods adapted for medical use in the form of tablets, drops, capsules, extract preparations, balms or in liquid form; food for medically restricted diets, food for diabetics, food supplements containing plant extracts, food supplements derived from plants or plant extracts, all aforesaid goods in the form of tablets, drops, capsules, extract preparations, balms or in liquid form; vitamin and mineral supplements; food and food supplements, namely herbal teas for medicinal purposes and medicinal teas; nutritional additives for use in foods and dietary supplements for human consumption; dietetic food supplements; dietary supplements; food supplements and dietary food supplements; mineral food supplements, food supplements based on amino acids, minerals and/or trace elements; medical plasters; materials for dressings, namely gauze and bandages; all purpose disinfectants; material for stopping teeth; dental waxACTIVE—
016Paper; cardboard; goods made from paper and cardboard, namely paper bags, coasters, figures and works of art; printed matter, namely books, magazines, journals, newspapers, periodicals, leaflets, reviews, manuals, catalogs and brochures in the fields of health and medicine; bookbinding material, namely bookbindings; photographs; stationery; adhesives for stationery or household purposes; artists' materials, namely artists' pastels, artists' pencils, artists' pens, painting sets for children; paint brushes; typewriters; office requisites except furniture, namely punches, staplers, erasers, desk pads, pencil sharpeners; instructional and teaching material, namely printed instructional and teaching material in the field of medicine and phytopharmacy; paper bags, envelopes and pouches for packaging; plastic bags and bubble packs for packagingACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 2, 2010DETHDEATH OF INTERNATIONAL REGISTRATION—
Mar 15, 2010MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Mar 13, 2010ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 3, 2009RFNTREFUSAL PROCESSED BY IB—
Aug 3, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Aug 3, 2009RFRRREFUSAL PROCESSED BY MPU—
Aug 1, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 31, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 28, 2009MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 24, 2009DOCKASSIGNED TO EXAMINER—
Jul 24, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 23, 2009LIMSLIMITATION OF GOODS/SERVICES FROM IB ENTERED—
Jul 23, 2009REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance